R/data.R

In BayesPPDSurv: Bayesian Power Prior Design for Survival Data

#' Melanoma Clinical Trials E1684 and E1690
#'
#' A dataset for the E1684 clinical trial (1996) and the E1690 clinical trial (2000) conducted to assess the utility of interferon alfa-2b (INF) as an adjuvant therapy following surgery for deep primary or regionally metastatic melanoma.
#' This dataset contains subjects in disease stage four only, i.e., regional lymph node recurrence at any interval
#' after appropriate surgery for primary melanoma of any depth. 
#'
#' @format A data frame with 381 rows and 5 variables:
#' \describe{
#'   \item{study}{study number (1684 or 1690)}
#'   \item{failtime}{time to relapse in years}
#'   \item{rfscens}{censoring indicator for time to relapse (0 = did not relapse, 1 = relapsed)}
#'   \item{trt}{treatment (1 if IFN and 0 if Observation)}
#'   \item{stratum}{stratum index (1 if number of positive nodes <= 2 and 2 if number of positive nodes >= 3}
#' }
#' @source Kirkwood, J. M., J. G. Ibrahim, V. K. Sondak, J. Richards, L. E. Flaherty, M. S. Ernstoff, T. J. Smith,
#' U. Rao, M. Steele, and R. H. Blum (2000, Jun). High- and low-dose interferon alfa-2b in high-risk 
#' melanoma: first analysis of intergroup trial e1690/s9111/c9190. Journal of Clinical Oncology 18 (12),
#' 2444–2458.
#' 
#' Kirkwood, J. M., M. H. Strawderman, M. S. Ernstoff, T. J. Smith, E. C. Borden, and R. H. Blum
#' (1996). Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern
#' cooperative oncology group trial est 1684. Journal of Clinical Oncology 14, 7–17.
"melanoma"